The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the p
A pharmacy benefit manager has thrown a legal punch at the Federal Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to
The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor
A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.
Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended to extend market exclusivity and block generic rivals.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.